Terms: = Prostate cancer AND CD74, ENSG00000019582, 972, protein 41, Ia-GAMMA, HLADG, DHLAG AND Treatment
31 results:
1. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [
Lv J; Yu H; Yin H; Shi Y; Shi H
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):919-927. PubMed ID: 37940684
[TBL] [Abstract] [Full Text] [Related]
2. Pretreatment information-aided automatic segmentation for online magnetic resonance imaging-guided prostate radiotherapy.
Yang B; Liu Y; Zhu J; Lu N; Dai J; Men K
Med Phys; 2024 Feb; 51(2):922-932. PubMed ID: 37449545
[TBL] [Abstract] [Full Text] [Related]
3. Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer.
Roy S; Wallis CJD; Morgan SC; Kishan AU; Le ATT; Malone J; Sun Y; Spratt DE; Saad F; Malone S
Prostate; 2023 Jul; 83(10):912-921. PubMed ID: 37071764
[TBL] [Abstract] [Full Text] [Related]
4. Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer.
Hung A; Candelieri D; Li Y; Alba P; Robison B; Agiri F; Perez C; Lee KM; Maxwell KN; Li W; Aggarwal H; Pridgen K; Reed SD; DuVall S; Wong YN; Lynch JA
Semin Oncol; 2023; 50(1-2):11-24. PubMed ID: 37055240
[TBL] [Abstract] [Full Text] [Related]
5. Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT.
Ayoub Z; Khader J; Bulbul M; Khauli RB; Andraos TY; Shamseddine A; Mukherji D; Geara FB
BMC Urol; 2022 Dec; 22(1):204. PubMed ID: 36503556
[TBL] [Abstract] [Full Text] [Related]
6. Medium-term Oncological Efficacy and Patient-reported Outcomes After Focal High-intensity Focused Ultrasound: The FOXPRO Trial.
Westhoff N; Ernst R; Kowalewski KF; Derigs F; Neuberger M; Nörenberg D; Popovic ZV; Ritter M; Stephan Michel M; von Hardenberg J
Eur Urol Focus; 2023 Mar; 9(2):283-290. PubMed ID: 36344395
[TBL] [Abstract] [Full Text] [Related]
7. Racial Analysis of Clinical and Biochemical Outcomes in Patients With prostate cancer Treated With Low-Dose-Rate Brachytherapy.
Kerans SJ; Samanta S; Vyfhuis MAL; Guerrero M; Bang CK; Mishra MV; Rana Z; Amin PP; Kwok Y; Naslund MJ; Molitoris JK
Int J Radiat Oncol Biol Phys; 2023 May; 116(1):87-95. PubMed ID: 36336224
[TBL] [Abstract] [Full Text] [Related]
8. mRNA and small RNA gene expression changes in peripheral blood to detect internal Ra-223 exposure.
Ostheim P; Miederer M; Schreckenberger M; Nestler T; Hoffmann MA; Lassmann M; Eberlein U; Barsegian V; Rump A; Majewski M; Port M; Abend M
Int J Radiat Biol; 2022; 98(5):900-912. PubMed ID: 34882512
[TBL] [Abstract] [Full Text] [Related]
9. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract] [Full Text] [Related]
10. Impact of non-adherence to radiotherapy on 1-year survival in cancer patients in Catalonia, Spain.
Borras JM; Font R; Solà J; Macia M; Tuset V; Arenas M; Eraso A; Verges R; Farré N; Pedro A; Mollà M; Algara M; Solé JM; Mira M; Espinàs JA
Radiother Oncol; 2020 Oct; 151():200-205. PubMed ID: 32771615
[TBL] [Abstract] [Full Text] [Related]
11. Candidates to salvage therapy after external-beam radiotherapy of prostate cancer: Predictors of local recurrence volume and metastasis-free survival.
Maoui M; Gonindard-Melodelima C; Chapet O; Colombel M; Ruffion A; Crouzet S; Rouvière O
Diagn Interv Imaging; 2021 Feb; 102(2):93-100. PubMed ID: 32534903
[TBL] [Abstract] [Full Text] [Related]
12. Secondary bladder and rectal cancer risk estimates following standard fractionated and moderately hypofractionated VMAT for prostate carcinoma.
Mazonakis M; Kachris S; Damilakis J
Med Phys; 2020 Jul; 47(7):2805-2813. PubMed ID: 32266979
[TBL] [Abstract] [Full Text] [Related]
13. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Mateo J; Porta N; Bianchini D; McGovern U; Elliott T; Jones R; Syndikus I; Ralph C; Jain S; Varughese M; Parikh O; Crabb S; Robinson A; McLaren D; Birtle A; Tanguay J; Miranda S; Figueiredo I; Seed G; Bertan C; Flohr P; Ebbs B; Rescigno P; Fowler G; Ferreira A; Riisnaes R; Pereira R; Curcean A; Chandler R; Clarke M; Gurel B; Crespo M; Nava Rodrigues D; Sandhu S; Espinasse A; Chatfield P; Tunariu N; Yuan W; Hall E; Carreira S; de Bono JS
Lancet Oncol; 2020 Jan; 21(1):162-174. PubMed ID: 31806540
[TBL] [Abstract] [Full Text] [Related]
14. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
Higano CS; Armstrong AJ; Sartor AO; Vogelzang NJ; Kantoff PW; McLeod DG; Pieczonka CM; Penson DF; Shore ND; Vacirca J; Concepcion RS; Tutrone RF; Nordquist LT; Quinn DI; Kassabian V; Scholz MC; Harmon M; Tyler RC; Chang NN; Tang H; Cooperberg MR
Cancer; 2019 Dec; 125(23):4172-4180. PubMed ID: 31483485
[TBL] [Abstract] [Full Text] [Related]
15. Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.
Sheng W; Kirschner-Hermanns R; Zhang H
World J Urol; 2019 Feb; 37(2):317-325. PubMed ID: 29951790
[TBL] [Abstract] [Full Text] [Related]
16. Enhancing the Potency and Specificity of Engineered T Cells for cancer treatment.
Sukumaran S; Watanabe N; Bajgain P; Raja K; Mohammed S; Fisher WE; Brenner MK; Leen AM; Vera JF
Cancer Discov; 2018 Aug; 8(8):972-987. PubMed ID: 29880586
[TBL] [Abstract] [Full Text] [Related]
17. Prevalence and initial prescription of psychotropics in patients with common cancers in Japan, based on a nationwide health insurance claims database.
Sato I; Onishi H; Yamada S; Kawakami K
Psychooncology; 2018 Feb; 27(2):450-457. PubMed ID: 28750146
[TBL] [Abstract] [Full Text] [Related]
18. cd74-NRG1 fusions in lung adenocarcinoma.
Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
[TBL] [Abstract] [Full Text] [Related]
19. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.
Nepple KG; Stephenson AJ; Kallogjeri D; Michalski J; Grubb RL; Strope SA; Haslag-Minoff J; Piccirillo JF; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Kibel AS
Eur Urol; 2013 Sep; 64(3):372-8. PubMed ID: 23506834
[TBL] [Abstract] [Full Text] [Related]
20. Racial variation in the quality of surgical care for prostate cancer.
Barocas DA; Gray DT; Fowke JH; Mercaldo ND; Blume JD; Chang SS; Cookson MS; Smith JA; Penson DF
J Urol; 2012 Oct; 188(4):1279-85. PubMed ID: 22902011
[TBL] [Abstract] [Full Text] [Related]
[Next]
